Literature DB >> 19331214

Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer.

Sherko Kuemmel1, Anke Thomas, Solveig Landt, Andrea Fuger, Peter Schmid, Monika Kriner, Jens-Uwe Blohmer, Jalid Sehouli, Gerhard Schaller, Werner Lichtenegger, Angela Köninger, Ilka Fuchs.   

Abstract

AIM: To study the impact of circulating vascular endothelial growth factors (VEGF) -A, -C and -D and their soluble receptors VEGFR-1/-2 on disease invasion and progression in patients with pre-invasive (CIN), invasive (PCC) and recurrent (RCC) cervical cancer. PATIENTS AND METHODS: Blood samples were obtained from 125 women, including 50 cases of CIN, 51 of PCC and 24 of RCC, before treatment. Soluble (s) biomarker levels were determined by ELISA and tested for correlation with histopathological factors.
RESULTS: With disease progression, sVEGF-A (p = 0.007) and sVEGFR-2 (p = 0.014) significantly increased, while sVEGF-D (p = 0.046) decreased. sVEGFR-2 levels were increased in node+ patients (p = 0.024) and in metastatic disease (p = 0.003). sVEGF-A values were higher in HPV+ cases (p = 0.019). In detecting disease invasiveness, sensitivity and specificity were 76% and 48% for sVEGF-A, 52% and 32% for sVEGF-D, 25% and 94% for sVEGF-C, 93% and 6% for sVEGFR-1 and 73% and 34% for sVEGFR-2, respectively.
CONCLUSION: In cervical neoplasia, a switch from a lymphangiogenic phenotype towards a hemangiogenic phenotype occurs with disease invasion and progression. The sensitivity and specificity values, however, seem not convincing enough to establish these factors as clinical markers for disease invasiveness in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19331214

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Developmental Programming: Does Prenatal Steroid Excess Disrupt the Ovarian VEGF System in Sheep?

Authors:  Hugo Héctor Ortega; Almudena Veiga-Lopez; Shilpa Sreedharan; Melisa María del Luján Velázquez; Natalia Raquel Salvetti; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2015-07-15       Impact factor: 4.285

2.  Altered expression of endogenous soluble vascular endothelial growth factor receptor-2 is involved in the progression of esophageal squamous cell carcinoma.

Authors:  Zhi-Yong Wu; Tao Chen; Qing Zhao; Jian-Hao Huang; Jie-Xin Chen; Chun-Peng Zheng; Xiu-E Xu; Jian-Yi Wu; Li-Yan Xu; En-Min Li
Journal:  J Histochem Cytochem       Date:  2013-02-07       Impact factor: 2.479

3.  Diagnostic Value of Circulating PIGF in Combination with Flt-1 in Early Cervical Cancer.

Authors:  Shou-Hua Yang; Xiao-Ling Wang; Jing Cai; Shao-Hai Wang
Journal:  Curr Med Sci       Date:  2020-10-29

Review 4.  Monoclonal antibodies in gynecological cancer: a critical point of view.

Authors:  Filippo Bellati; Chiara Napoletano; Maria Luisa Gasparri; Valeria Visconti; Ilaria Grazia Zizzari; Ilary Ruscito; Jlenia Caccetta; Aurelia Rughetti; Pierluigi Benedetti-Panici; Marianna Nuti
Journal:  Clin Dev Immunol       Date:  2011-12-26

5.  Plasma vascular endothelial growth factor dysregulation in defining aggressiveness of head and neck squamous cell carcinoma.

Authors:  Boonchu Kulapaditharom; Vipa Boonkitticharoen; Chanika Sritara
Journal:  J Oncol       Date:  2011-12-15       Impact factor: 4.375

6.  High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer.

Authors:  Yun-Zhi Dang; Ying Zhang; Jian-Ping Li; Jing Hu; Wei-Wei Li; Pei Li; Li-Chun Wei; Mei Shi
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

7.  Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.

Authors:  Hanna Sallinen; Tommi Heikura; Jonna Koponen; Veli-Matti Kosma; Seppo Heinonen; Seppo Ylä-Herttuala; Maarit Anttila
Journal:  BMC Cancer       Date:  2014-09-23       Impact factor: 4.430

8.  The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.

Authors:  Beata Kotowicz; Malgorzata Fuksiewicz; Joanna Jonska-Gmyrek; Mariusz Bidzinski; Maria Kowalska
Journal:  Tumour Biol       Date:  2015-08-20

Review 9.  Profile of bevacizumab and its potential in the treatment of cervical cancer.

Authors:  Christine M Fisher; Tracey E Schefter
Journal:  Onco Targets Ther       Date:  2015-11-19       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.